IL150516A0 - The use of fumaric acid derivatives for treatment of mitochondrial diseases - Google Patents
The use of fumaric acid derivatives for treatment of mitochondrial diseasesInfo
- Publication number
- IL150516A0 IL150516A0 IL15051600A IL15051600A IL150516A0 IL 150516 A0 IL150516 A0 IL 150516A0 IL 15051600 A IL15051600 A IL 15051600A IL 15051600 A IL15051600 A IL 15051600A IL 150516 A0 IL150516 A0 IL 150516A0
- Authority
- IL
- Israel
- Prior art keywords
- fumaric acid
- treatment
- mitochondrial diseases
- acid derivatives
- sdh
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10000577A DE10000577A1 (de) | 2000-01-10 | 2000-01-10 | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
PCT/EP2000/012504 WO2001051047A1 (de) | 2000-01-10 | 2000-12-11 | Verwendung von fumarsäurederivaten zur behandlung mitochondrialer krankheiten |
Publications (1)
Publication Number | Publication Date |
---|---|
IL150516A0 true IL150516A0 (en) | 2003-02-12 |
Family
ID=7627026
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15051600A IL150516A0 (en) | 2000-01-10 | 2000-12-11 | The use of fumaric acid derivatives for treatment of mitochondrial diseases |
IL150516A IL150516A (en) | 2000-01-10 | 2002-07-02 | 3, 4 - epoxy alkanoic acid ester, fragrant component, fragrant product containing those, and application of those compounds |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL150516A IL150516A (en) | 2000-01-10 | 2002-07-02 | 3, 4 - epoxy alkanoic acid ester, fragrant component, fragrant product containing those, and application of those compounds |
Country Status (28)
Country | Link |
---|---|
US (1) | US6858750B2 (bg) |
EP (1) | EP1248606B1 (bg) |
JP (1) | JP2003529556A (bg) |
CN (1) | CN1433303A (bg) |
AT (1) | ATE329590T1 (bg) |
AU (1) | AU772409B2 (bg) |
BG (1) | BG65468B1 (bg) |
BR (1) | BR0016935A (bg) |
CA (1) | CA2390886C (bg) |
CY (1) | CY1105462T1 (bg) |
CZ (1) | CZ303680B6 (bg) |
DE (2) | DE10000577A1 (bg) |
DK (1) | DK1248606T3 (bg) |
EE (1) | EE05051B1 (bg) |
ES (1) | ES2265367T3 (bg) |
HU (1) | HU229138B1 (bg) |
IL (2) | IL150516A0 (bg) |
MX (1) | MXPA02006695A (bg) |
NO (1) | NO326875B1 (bg) |
NZ (1) | NZ518781A (bg) |
PL (1) | PL223342B1 (bg) |
PT (1) | PT1248606E (bg) |
RS (1) | RS50185B (bg) |
RU (1) | RU2218918C1 (bg) |
SI (1) | SI1248606T1 (bg) |
SK (1) | SK286719B6 (bg) |
WO (1) | WO2001051047A1 (bg) |
ZA (1) | ZA200205481B (bg) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
PL392750A1 (pl) * | 2001-01-12 | 2011-05-23 | Fumapharm Ag | Amidy kwasu fumarowego |
DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
DE10217314A1 (de) * | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
US7224426B2 (en) * | 2002-07-31 | 2007-05-29 | Dai Nippon Printing Co., Ltd. | Optical element |
PL1663197T3 (pl) * | 2003-09-09 | 2008-09-30 | Biogen Idec Int Gmbh | Zastosowanie pochodnych kwasu fumarowego do leczenia niewydolności serca oraz astmy |
DE202005022112U1 (de) * | 2004-10-08 | 2014-04-24 | Forward Pharma A/S | Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung, umfassend einen Fumarsaureester |
DE602006011910D1 (de) * | 2005-07-07 | 2010-03-11 | Aditech Pharma Ag | Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung |
WO2007006307A2 (en) * | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
JP5213137B2 (ja) * | 2006-12-06 | 2013-06-19 | コーネル リサーチ ファウンデーション, インコーポレイテッド | 中程度の持続時間の神経筋遮断剤およびそのアンタゴニスト |
EP4137819A1 (en) | 2007-02-08 | 2023-02-22 | Biogen MA Inc. | Compositions and uses for treating multiple sclerosis |
WO2008096271A2 (en) * | 2007-02-08 | 2008-08-14 | Ralf Gold | Neuroprotection in demyelinating diseases |
EP2334378B1 (en) * | 2008-08-19 | 2014-04-09 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
US20120034274A1 (en) * | 2009-01-09 | 2012-02-09 | Forward Pharma A/S | Pharmaceutical composition comprising one or more fumaric acid esters |
RU2743637C2 (ru) | 2009-01-09 | 2021-02-20 | Фвп Ип Апс | Фармацевтический состав, содержащий один или более эфиров фумаровой кислоты в разлагаемой матрице |
US8592451B2 (en) | 2009-03-17 | 2013-11-26 | Cornell University | Reversible nondepolarizing neuromuscular blockade agents and methods for their use |
CN102573794B (zh) | 2009-08-19 | 2017-03-15 | 康奈尔大学 | 供生理注射用的半胱氨酸 |
WO2012149478A2 (en) * | 2011-04-28 | 2012-11-01 | Serket Pharma, Llc | Agents useful for treating friedreich's ataxia and other neurodegenerative diseases |
RS56972B1 (sr) | 2011-06-08 | 2018-05-31 | Biogen Ma Inc | Postupak za pripremu visoko-čistog i kristalnog dimetil fumarata |
EP2782561A1 (en) | 2011-11-24 | 2014-10-01 | Synthon BV | Controlled release particles comprising dimethyl fumarate |
US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
AU2013203445C1 (en) * | 2012-02-07 | 2017-04-20 | Biogen Ma Inc. | Pharmaceutical compositions containing dimethyl fumarate |
NZ629728A (en) | 2012-02-07 | 2016-07-29 | Xenoport Inc | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use |
CA2882713A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
EP2887933A1 (en) | 2012-08-22 | 2015-07-01 | XenoPort, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
ES2733961T3 (es) | 2012-12-21 | 2019-12-03 | Biogen Ma Inc | Derivados de fumarato sustituidos con deuterio |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
RS57497B1 (sr) | 2013-03-14 | 2018-10-31 | Alkermes Pharma Ireland Ltd | Prolekovi fumarata i njihova upotreba u lečenju raznih bolesti |
WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
US9302977B2 (en) | 2013-06-07 | 2016-04-05 | Xenoport, Inc. | Method of making monomethyl fumarate |
WO2014205392A1 (en) | 2013-06-21 | 2014-12-24 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
EP3041467A1 (en) | 2013-09-06 | 2016-07-13 | XenoPort, Inc. | Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use |
AU2015218587B2 (en) | 2014-02-24 | 2017-04-27 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
WO2016061393A1 (en) | 2014-10-15 | 2016-04-21 | Xenoport, Inc. | Fumarate compounds, pharmaceutical compositions, and methods of use |
HUE055210T2 (hu) | 2015-02-08 | 2021-11-29 | Alkermes Pharma Ireland Ltd | Monometilfumarát prodrug készítmények |
ES2826825T3 (es) | 2015-03-27 | 2021-05-19 | Symbionyx Pharmaceuticals Inc | Composiciones y métodos para el tratamiento de la psoriasis |
US10085961B2 (en) | 2015-06-01 | 2018-10-02 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of dimethyl fumarate |
WO2017060400A1 (en) | 2015-10-07 | 2017-04-13 | Neurovive Pharmaceutical Ab | Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions |
IT201700087359A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
IT201700087376A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
RU2674286C1 (ru) * | 2018-03-20 | 2018-12-07 | Исмагилов Искандар Халиуллович | Средство для лечения заболевания, обусловленного нарушением окислительного стресса |
RU2742745C1 (ru) * | 2019-09-24 | 2021-02-10 | Акционерное общество "Исследовательский Институт Химического Разнообразия" | Лекарственная форма в виде капсулы, содержащая таблетки с диметилфурмаратом |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2530372A1 (de) * | 1975-07-08 | 1977-01-13 | Walter Dr Schweckendiek | Pharmazeutische zubereitungen zur behandlung von psoriasis |
DE2621214C3 (de) * | 1976-05-13 | 1981-11-12 | Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen | Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen |
CH664150A5 (de) * | 1985-01-15 | 1988-02-15 | Peter Paul Prof Dr Speiser | Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen. |
JPS61194020A (ja) * | 1985-02-22 | 1986-08-28 | Dai Ichi Seiyaku Co Ltd | 網膜症治療剤 |
US4959389A (en) * | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
IT1251166B (it) * | 1991-08-09 | 1995-05-04 | Chiesi Farma Spa | Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono |
EP0750616B1 (en) * | 1994-03-16 | 2001-05-30 | CeNeS Limited | Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds |
DE19721099C2 (de) * | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
EP1032403B1 (en) * | 1997-10-24 | 2012-05-02 | John P. Blass | Nutritional supplement for cerebral metabolic insufficiencies |
DE19839566C2 (de) * | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
US6812248B2 (en) * | 2000-07-05 | 2004-11-02 | John Hopkins University School Of Medicine | Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes |
-
2000
- 2000-01-10 DE DE10000577A patent/DE10000577A1/de not_active Withdrawn
- 2000-12-11 RU RU2002121493/15A patent/RU2218918C1/ru not_active IP Right Cessation
- 2000-12-11 MX MXPA02006695A patent/MXPA02006695A/es active IP Right Grant
- 2000-12-11 PL PL356714A patent/PL223342B1/pl unknown
- 2000-12-11 NZ NZ518781A patent/NZ518781A/en not_active IP Right Cessation
- 2000-12-11 US US10/148,858 patent/US6858750B2/en not_active Expired - Lifetime
- 2000-12-11 HU HU0204182A patent/HU229138B1/hu not_active IP Right Cessation
- 2000-12-11 ES ES00991160T patent/ES2265367T3/es not_active Expired - Lifetime
- 2000-12-11 SI SI200030869T patent/SI1248606T1/sl unknown
- 2000-12-11 BR BR0016935-8A patent/BR0016935A/pt not_active Application Discontinuation
- 2000-12-11 WO PCT/EP2000/012504 patent/WO2001051047A1/de active IP Right Grant
- 2000-12-11 PT PT00991160T patent/PT1248606E/pt unknown
- 2000-12-11 CA CA002390886A patent/CA2390886C/en not_active Expired - Fee Related
- 2000-12-11 EE EEP200200333A patent/EE05051B1/xx not_active IP Right Cessation
- 2000-12-11 RS YUP-514/02A patent/RS50185B/sr unknown
- 2000-12-11 SK SK652-2002A patent/SK286719B6/sk not_active IP Right Cessation
- 2000-12-11 CZ CZ20021522A patent/CZ303680B6/cs not_active IP Right Cessation
- 2000-12-11 JP JP2001551471A patent/JP2003529556A/ja active Pending
- 2000-12-11 IL IL15051600A patent/IL150516A0/xx active IP Right Grant
- 2000-12-11 EP EP00991160A patent/EP1248606B1/de not_active Expired - Lifetime
- 2000-12-11 AU AU31566/01A patent/AU772409B2/en not_active Ceased
- 2000-12-11 AT AT00991160T patent/ATE329590T1/de active
- 2000-12-11 DK DK00991160T patent/DK1248606T3/da active
- 2000-12-11 DE DE50013000T patent/DE50013000D1/de not_active Expired - Lifetime
- 2000-12-11 CN CN00818784A patent/CN1433303A/zh active Pending
-
2002
- 2002-05-07 NO NO20022175A patent/NO326875B1/no not_active IP Right Cessation
- 2002-05-09 BG BG106685A patent/BG65468B1/bg unknown
- 2002-07-02 IL IL150516A patent/IL150516A/en not_active IP Right Cessation
- 2002-07-09 ZA ZA200205481A patent/ZA200205481B/xx unknown
-
2006
- 2006-08-11 CY CY20061101141T patent/CY1105462T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL150516A0 (en) | The use of fumaric acid derivatives for treatment of mitochondrial diseases | |
UA74346C2 (uk) | Похідні амінодикарбонових кислот, їх застосування та лікарський засіб | |
BR0108452A (pt) | Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva | |
NZ514234A (en) | N-cyanomethylamides as protease inhibitors | |
TR199801642T2 (xx) | Tedavide faydal� olan karbamik asitlerin azabisiklik esterleri. | |
IL148103A0 (en) | Novel dicarboxylic acid derivatives with pharmaceutical properties | |
ES2103587T3 (es) | Composiciones terapeuticas ingeribles, estables y absorbibles de nadh y de nadph. | |
CA2445145A1 (en) | Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes | |
CY1107600T1 (el) | Κρεμα για τη θepαπεια δερματος τραυματισμενου απο τον ηλιο | |
WO2003037323A3 (en) | Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction | |
MXPA02006249A (es) | Nuevos derivados de azabiciclooctano, utiles en el tratamiento de arritmias cardiacas. | |
ATE311866T1 (de) | Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln zur behandlung von erkrankungen rheumatischer natur | |
DE60122917D1 (de) | Fermentative herstellung von d-p-hydroxyphenylglycin und d-phenylglycin | |
CY1106168T1 (el) | Συνθεση για την προληψη και/ή θepαπεια αγγειακων ασθενειων που συνισταται απο προπιονυλ l-καρνιτινη και συνενζυμο q10 | |
IL163344A (en) | 2-(4-(3-cyclopentyloxy-4-difluoromethoxyphenyl)-4-cyanopiperidin-1-yl)acetic acid derivative compounds, process for their synthesis and compositions comprising the compounds as the active ingredient | |
MY122830A (en) | Process for the preparation of (alpha)-(2-4-disulfophenyl)-n-tert-butylnitrone and pharmaceutically acceptable salts thereof | |
MXPA03002047A (es) | Fenilciclohexanocarboxamidas substituidas y su uso. | |
ATE330597T1 (de) | Verwendung von fibrate zur herstellung eines arzneimittel zur behandlung von kongestiven herzversagens | |
NO20044555L (no) | Kombinasjonsprodukt omfattende en antikoagulant og anti-arrytmiske oksabispidener | |
UA41037A (uk) | Препарат для лікування захворювань порожнини роту | |
YU89903A (sh) | Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa i -gama aktivatori u lečenju dijabetesa | |
HUP0301647A2 (hu) | Fibrátok alkalmazása kongesztív szívelégtelenség kezelésére használható gyógyszerkészítmény előállítására |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |